Newton001: Biomarkers of treatment naive psychosis.

精神病的第一次发作可能是精神分裂症最重要的阶段，除非在此阶段建立有效的治疗，否则许多患者会出现不利的临床结果。如果我们能够了解与FEP相关的生物标志物和随后对治疗的反应，我们也许能够开发出预测患者对哪种治疗反应最好的方法。然而，为了理解这一点，我们需要在患者接受药物治疗之前检查患者的样本，否则就不清楚哪些变化是由疾病/发作引起的，哪些是由处方药物引起的。我们收集了未经治疗的精神病患者（在接受药物治疗之前）的血液样本（RNA，DNA和血清），并在药物治疗后随访8周（N=80）和1年（N=30）。这组患者是独特的，能够研究不受治疗药物影响的生物标志物可能使我们更好地了解精神病的原因和潜在的潜在风险。

The First Episode of Psychosis is perhaps the most important stage of schizophrenia, unless effective treatment is established during this phase many patients develop an unfavourable clinical outcome. If we can understand the biological markers associated with FEP and subsequent response to treatment, we maybe able to develop ways of predicting which treatment patients will respond best to. However, to understand this we need to examine samples from patients before they undergo drug treatment, as otherwise it is unclear what changes are due to the disorder/episode and what are due to the prescribed medication. We have collected blood samples (RNA, DNA and serum) from psychosis patients who are treatment naïve (before they received drug treatment for the disorder), and who have been followed for 8 weeks (N=80) and one year (N=30) after drug treatment. This group of patients is unique and being able to study biomarkers unaffected by the drugs given as treatments may allow us greater understanding of the causes and potential underlying risks for psychosis.